🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPharmacology & MechanismsGLP-1R desensitization — β-arrestin-mediated internalization

GLP-1R desensitization — β-arrestin-mediated internalization

NeuroNate Mon, Jun 8, 2026 at 3:41 AM 18 replies 396 viewsPage 1 of 4
NeuroNate
Senior Member
2,890
16,789
Dec 2023
Chicago, IL
Jun 8, 2026 at 3:41 AM#1

This gets cited here weekly, usually second-hand, so it is worth setting out what it does and does not establish.

The mechanism is more central than most summaries suggest. Receptor agonism in the arcuate nucleus activates POMC neurons and inhibits AgRP/NPY signalling, and the downstream MC4R pathway is the same one disrupted in monogenic obesity — convergent genetic evidence that the target is the right one. Peripherally there is glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying, but the gastric component largely adapts over months while the central effect persists, which is why the durable effect is appetite rather than fullness.

Where I think it is weakest: the subgroup findings are the part I trust least — with enough subgroups something is always significant, and these were not all pre-registered.

What I am trying to establish is which effects tachyphylax and which persist, because the answer explains why tolerability improves while the appetite effect keeps working. Numbers rather than impressions, if you have them.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
13 8jason_paloalto, Dr.LeslieOBGYN, MikeNYC_runner and 10 others
Reply Quote Save Share Report
VendorMark
Senior Member
3,456
14,567
Jan 2024
Texas
Online
Jun 8, 2026 at 3:56 AM#2
NeuroNate said:
The mechanism is more central than most summaries suggest.

Pharmacist here. I want to add the drug interaction perspective on the pharmacology.

Key points from a pharmacokinetic standpoint:

  • GLP-1 agonists delay gastric emptying, which can affect Tmax of co-administered oral medications
  • Monitor patients on warfarin (INR), levothyroxine (TSH), and oral contraceptives during dose titration
  • The albumin-binding mechanism of semaglutide (C-18 fatty acid linker) gives it the ~168-hour half-life that enables weekly dosing
  • Steady state is reached at approximately 4-5 weeks after dose initiation or adjustment

Re: the pharmacology specifically — the pharmacology here is well-characterized and the clinical implications are straightforward.

Last edited: Jun 8, 2026 at 5:56 AM
12 7KristenIndy, MarkLI_maint, Dr.PeteFamMed and 9 others
Reply Quote Save Share Report
LibrarianMeg
Senior Member
1,678
7,890
Mar 2024
Baltimore, MD
Jun 8, 2026 at 4:11 AM#3
NeuroNate said:
The mechanism is more central than most summaries suggest.

This is where I part company with the consensus forming above. The pharmacokinetics explain nearly every practical question asked here. Albumin binding above 99% slows clearance enough to make weekly dosing possible; a terminal half-life near a week means four to five weeks to steady state and therefore a four-week titration interval; subcutaneous bioavailability around 89% means injection site barely matters. Those three facts answer most timing questions before they are asked.

11 6julia.endo, JessicaM_2024, TomFromTexas and 8 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
andrew_nyc
Member
534
2,345
Apr 2024
New York, NY
Jun 8, 2026 at 4:26 AM#4
LibrarianMeg said:
The pharmacokinetics explain nearly every practical question asked here.

Receptor pharmacology relevant to the pharmacology: semaglutide is a GLP-1R agonist with a C-18 fatty acid chain that enables albumin binding (>99%), creating a depot effect with a ~168-hour half-life enabling weekly dosing[1].

Tirzepatide is a dual GIP/GLP-1R agonist with higher GIP affinity (5:1 GIP:GLP-1 potency ratio). The GIP component may enhance beta-cell function and adipocyte lipid metabolism beyond what GLP-1 alone achieves.

For the pharmacology, the pharmacology explains the clinical differences between these agents.

References:
[1] Lau J, et al. J Med Chem. 2015;58(18):7370-7380.
10 5julia.endo, JessicaM_2024, TomFromTexas and 7 others
Reply Quote Save Share Report
robert_kc
Member
289
1,234
Oct 2024
Kansas City, MO
Jun 8, 2026 at 5:55 AM#5
VendorMark said:
I want to add the drug interaction perspective on the pharmacology.

Same experience, arrived at from the opposite direction.

Last edited: Jun 8, 2026 at 7:55 AM
9 4PharmHunterJen, TomTeleRx, DoseLogDan and 6 others
Reply Quote Save Share Report

Similar Threads

Biased agonism at GLP-1R — Gs vs β-arrestin signaling balance13 replies
Semaglutide albumin binding and the C-18 fatty acid linker17 replies
GIP receptor pharmacology — why GIP agonism enhances GLP-113 replies
Glucagon receptor signaling — hepatic glycogenolysis and lipolysis16 replies
Structure-activity relationships of GLP-1 analogs12 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register